Abstract The 3435C→ T polymorphism at the multidrug resistance gene 1 (MDR1) was
examined in 74 patients with human immunodeficiency virus who initiated atazanavir …

Introduction: HIV-infected patients receiving protease inhibitors may benefit from therapeutic
drug monitoring-assisted dose adjustment to achieve target plasma concentrations …

Background: Hyperbilirubinemia is frequently seen in patients treated with atazanavir (ATV).
Polymorphisms at the uridin-glucoronosyl-transferase 1A1 (UGT1A1) and multidrug …

Background. High prevalence of severe atazanavir-associated hyperbilirubinemia in Asians
with low prevalence of the UDP-glucuronosyltransferase (UGT) 1A1* 28 polymorphism …

Background HIV-1-infected patients vary considerably by their response to antiretroviral
treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This …

Atazanavir is a first-line HIV protease inhibitor commonly co-dosed with ritonavir. Ritonavir
inhibits atazanavir metabolism, decreasing variability and increasing plasma concentrations …

Objectives The objective of this study was to compare atazanavir pharmacokinetics in
genetically determined CYP3A5 expressors versus non-expressors. Methods HIV-negative …

A recent study with 69 Japanese liver transplants treated with tacrolimus found that the
MDR1 3435 C> T polymorphism, but not the MDR1 2677 G> T polymorphism, was …

The variability of P-glycoprotein expression between individuals is linked to a C3435T
polymorphism of the human MDR1 gene. Concentration of P-glycoprotein in intestinal …

The objective of this study was to evaluate virological and pharmacological determinants of
a 24-week virological response to unboosted atazanavir (ATV) in highly drug-experienced …